Available from: 16.Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ
Emerging Indications: What Physicians Need to Know Beyond Diabetes and Obesity GLP-1s are now being formally studied for Alzheimers disease risk reduction, MASH (metabolic-associated steatohepatitis), osteoarthritis, obstructive sleep apnea, peripheral artery disease, and autoimmune conditions
That said, the following titration table reflects the prevailing clinical approach used by longevity-focused practitioners, calibrated against the available pharmacological data
Retatrutide (LY3437943), developed by Eli Lilly, is a first-in-class triple GIP/GLP-1/glucagon receptor agonist
They can assess your medical history, determine the appropriate dosage, and provide guidance on injection technique
Common doses land on clean syringe readings, and the vial lasts a reasonable number of draws